O	O	0	5	Renal	Renal	B-NP	JJ	O	3	NMOD	O
O	O	6	10	cell	cell	I-NP	NN	O	3	NMOD	O
O	O	11	20	carcinoma	carcinoma	I-NP	NN	O	6	NMOD	O
O	O	20	21	-	-	B-NP	HYPH	O	3	P	O
O	O	21	28	derived	derive	I-NP	VBN	O	6	NMOD	O
O	O	29	41	gangliosides	ganglioside	I-NP	NNS	O	7	SUB	O
O	O	42	50	suppress	suppress	B-VP	VBP	O	0	ROOT	O
T5	B-Entity	51	58	nuclear	nuclear	B-NP	JJ	B-protein	12	NMOD	B-protein
T5	I-Entity	59	65	factor	factor	I-NP	NN	I-protein	12	NMOD	I-protein
T5	I-Entity	65	66	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
T5	I-Entity	66	72	kappaB	kappaB	I-NP	NN	I-protein	12	NMOD	I-protein
O	O	73	83	activation	activation	I-NP	NN	O	7	OBJ	O
O	O	84	86	in	in	B-PP	IN	O	12	NMOD	O
O	O	87	88	T	T	B-NP	NN	B-cell_type	15	NMOD	B-cell_type
O	O	89	94	cells	cell	I-NP	NNS	I-cell_type	13	PMOD	I-cell_type
O	O	94	95	.	.	O	.	O	7	P	O

O	O	97	107	Activation	Activation	B-NP	NN	O	13	SUB	O
O	O	108	110	of	of	B-PP	IN	O	1	NMOD	O
O	O	111	114	the	the	B-NP	DT	O	7	NMOD	O
T6	B-Entity	115	128	transcription	transcription	I-NP	NN	B-protein	7	NMOD	B-protein
T6	I-Entity	129	135	factor	factor	I-NP	NN	I-protein	7	NMOD	I-protein
T6	I-Entity	136	143	nuclear	nuclear	B-NP	JJ	I-protein	7	NMOD	I-protein
T6	I-Entity	144	150	factor	factor	I-NP	NN	I-protein	9	NMOD	I-protein
T6	I-Entity	150	151	-	-	O	HYPH	O	9	P	O
T6	I-Entity	151	157	kappaB	kappaB	B-NP	NN	B-protein	2	PMOD	B-protein
O	O	158	159	(	(	O	(	O	12	DEP	O
T7	B-Entity	159	167	NFkappaB	NFkappaB	B-NP	NN	B-protein	12	DEP	B-protein
O	O	167	168	)	)	O	)	O	9	NMOD	O
O	O	169	171	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	172	180	impaired	impair	I-VP	VBN	O	13	VC	O
O	O	181	183	in	in	B-PP	IN	O	14	VMOD	O
O	O	184	185	T	T	B-NP	NN	B-cell_type	17	NMOD	B-cell_type
O	O	186	191	cells	cell	I-NP	NNS	I-cell_type	15	PMOD	I-cell_type
O	O	192	196	from	from	B-PP	IN	O	17	NMOD	O
O	O	197	205	patients	patient	B-NP	NNS	O	18	PMOD	O
O	O	206	210	with	with	B-PP	IN	O	19	NMOD	O
O	O	211	216	renal	renal	B-NP	JJ	O	23	NMOD	O
O	O	217	221	cell	cell	I-NP	NN	O	23	NMOD	O
O	O	222	232	carcinomas	carcinoma	I-NP	NNS	O	20	PMOD	O
O	O	233	234	(	(	O	(	O	26	DEP	O
O	O	234	238	RCCs	RCC	B-NP	NNS	O	26	DEP	O
O	O	238	239	)	)	O	)	O	23	NMOD	O
O	O	239	240	.	.	O	.	O	13	P	O

O	O	241	243	In	In	B-PP	IN	O	19	VMOD	O
O	O	244	255	circulating	circulate	B-VP	VBG	B-cell_type	4	NMOD	B-cell_type
O	O	256	257	T	T	B-NP	NN	I-cell_type	4	NMOD	I-cell_type
O	O	258	263	cells	cell	I-NP	NNS	I-cell_type	1	PMOD	I-cell_type
O	O	264	268	from	from	B-PP	IN	O	4	NMOD	O
O	O	269	270	a	a	B-NP	DT	O	7	NMOD	O
O	O	271	277	subset	subset	I-NP	NN	O	5	PMOD	O
O	O	278	280	of	of	B-PP	IN	O	7	NMOD	O
O	O	281	289	patients	patient	B-NP	NNS	O	8	PMOD	O
O	O	290	294	with	with	B-PP	IN	O	9	NMOD	O
O	O	295	299	RCCs	RCC	B-NP	NNS	O	10	PMOD	O
O	O	299	300	,	,	O	,	O	19	P	O
O	O	301	304	the	the	B-NP	DT	O	14	NMOD	O
O	O	305	316	suppression	suppression	I-NP	NN	O	19	SUB	O
O	O	317	319	of	of	B-PP	IN	O	14	NMOD	O
T8	B-Entity	320	328	NFkappaB	NFkappaB	B-NP	NN	B-protein	18	NMOD	B-protein
O	O	329	336	binding	binding	I-NP	NN	O	18	NMOD	O
O	O	337	345	activity	activity	I-NP	NN	O	15	PMOD	O
O	O	346	348	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	349	359	downstream	downstream	B-ADVP	RB	O	19	PRD	O
O	O	360	364	from	from	B-PP	IN	O	20	AMOD	O
O	O	365	368	the	the	B-NP	DT	O	23	NMOD	O
O	O	369	377	stimulus	stimulus	I-NP	NN	O	26	NMOD	O
O	O	377	378	-	-	B-NP	HYPH	O	26	NMOD	O
O	O	378	385	induced	induce	I-NP	VBN	O	26	NMOD	O
O	O	386	397	degradation	degradation	I-NP	NN	O	21	PMOD	O
O	O	398	400	of	of	B-PP	IN	O	26	NMOD	O
O	O	401	404	the	the	B-NP	DT	O	31	NMOD	O
O	O	405	416	cytoplasmic	cytoplasmic	I-NP	JJ	B-protein	31	NMOD	B-protein
O	O	417	423	factor	factor	I-NP	NN	I-protein	31	NMOD	I-protein
T1	B-Protein	424	436	IkappaBalpha	IkappaBalpha	I-NP	NN	B-protein	27	PMOD	B-protein
O	O	436	437	.	.	O	.	O	19	P	O

O	O	438	443	Tumor	Tumor	B-NP	NN	B-protein	5	NMOD	B-protein
O	O	443	444	-	-	O	HYPH	I-protein	5	P	I-protein
O	O	444	451	derived	derive	B-VP	VBN	I-protein	5	NMOD	I-protein
O	O	452	459	soluble	soluble	B-NP	JJ	I-protein	5	NMOD	I-protein
O	O	460	468	products	product	I-NP	NNS	I-protein	10	SUB	I-protein
O	O	469	473	from	from	B-PP	IN	O	5	NMOD	O
O	O	474	482	cultured	culture	B-NP	VBN	O	9	NMOD	O
O	O	483	486	RCC	RCC	I-NP	NN	O	9	NMOD	O
O	O	487	495	explants	explant	I-NP	NNS	O	6	PMOD	O
O	O	496	503	inhibit	inhibit	B-VP	VBP	O	0	ROOT	O
T9	B-Entity	504	512	NFkappaB	NFkappaB	B-NP	NN	B-protein	12	NMOD	B-protein
O	O	513	521	activity	activity	I-NP	NN	O	10	OBJ	O
O	O	522	524	in	in	B-PP	IN	O	12	NMOD	O
O	O	525	526	T	T	B-NP	NN	B-cell_type	15	NMOD	B-cell_type
O	O	527	532	cells	cell	I-NP	NNS	I-cell_type	13	PMOD	I-cell_type
O	O	533	537	from	from	B-PP	IN	O	15	NMOD	O
O	O	538	545	healthy	healthy	B-NP	JJ	O	18	NMOD	O
O	O	546	556	volunteers	volunteer	I-NP	NNS	O	16	PMOD	O
O	O	556	557	,	,	O	,	O	10	P	O
O	O	558	565	despite	despite	B-PP	IN	O	10	VMOD	O
O	O	566	567	a	a	B-NP	DT	O	23	NMOD	O
O	O	568	574	normal	normal	I-NP	JJ	O	23	NMOD	O
O	O	575	580	level	level	I-NP	NN	O	20	PMOD	O
O	O	581	583	of	of	B-PP	IN	O	23	NMOD	O
O	O	584	592	stimulus	stimulus	B-NP	NN	O	29	NMOD	O
O	O	592	593	-	-	B-NP	HYPH	O	29	NMOD	O
O	O	593	600	induced	induce	I-NP	VBN	O	29	NMOD	O
T2	B-Protein	601	613	IkappaBalpha	IkappaBalpha	I-NP	NN	B-protein	29	NMOD	B-protein
O	O	614	625	degradation	degradation	I-NP	NN	O	24	PMOD	O
O	O	626	628	in	in	B-PP	IN	O	23	NMOD	O
O	O	629	634	these	these	B-NP	DT	O	32	NMOD	O
O	O	635	640	cells	cell	I-NP	NNS	O	30	PMOD	O
O	O	640	641	.	.	O	.	O	10	P	O

O	O	642	645	The	The	B-NP	DT	O	3	NMOD	O
O	O	646	656	inhibitory	inhibitory	I-NP	JJ	O	3	NMOD	O
O	O	657	662	agent	agent	I-NP	NN	O	4	SUB	O
O	O	663	666	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	667	674	several	several	B-NP	JJ	O	6	NMOD	O
O	O	675	683	features	feature	I-NP	NNS	O	4	OBJ	O
O	O	684	698	characteristic	characteristic	B-ADJP	JJ	O	6	NMOD	O
O	O	699	701	of	of	B-PP	IN	O	7	AMOD	O
O	O	702	703	a	a	B-NP	DT	O	10	NMOD	O
O	O	704	715	ganglioside	ganglioside	I-NP	NN	O	8	PMOD	O
O	O	715	716	,	,	O	,	O	6	P	O
O	O	717	726	including	include	B-PP	VBG	O	6	NMOD	O
O	O	727	738	sensitivity	sensitivity	B-NP	NN	O	25	NMOD	O
O	O	739	741	to	to	B-PP	TO	O	13	NMOD	O
O	O	742	755	neuraminidase	neuraminidase	B-NP	NN	B-protein	17	NMOD	B-protein
O	O	756	759	but	but	B-NP	CC	O	17	NMOD	O
O	O	760	763	not	not	I-NP	RB	O	14	PMOD	O
O	O	764	772	protease	protease	B-NP	NN	B-protein	17	NMOD	B-protein
O	O	773	782	treatment	treatment	I-NP	NN	O	17	NMOD	O
O	O	782	783	;	;	O	:	O	25	P	O
O	O	784	798	hydrophobicity	hydrophobicity	B-NP	NN	O	25	NMOD	O
O	O	798	799	;	;	O	:	O	25	P	O
O	O	800	803	and	and	O	CC	O	25	NMOD	O
O	O	804	813	molecular	molecular	B-NP	JJ	O	25	NMOD	O
O	O	814	820	weight	weight	I-NP	NN	O	12	PMOD	O
O	O	821	825	less	less	B-NP	JJR	O	25	NMOD	O
O	O	826	830	than	than	I-NP	IN	O	26	AMOD	O
O	O	831	832	3	3	I-NP	CD	O	29	NMOD	O
O	O	833	836	kDa	kDa	I-NP	NN	O	27	PMOD	O
O	O	836	837	.	.	O	.	O	4	P	O

O	O	838	844	Indeed	Indeed	B-ADVP	RB	O	4	VMOD	O
O	O	844	845	,	,	O	,	O	4	P	O
O	O	846	848	we	we	B-NP	PRP	O	4	SUB	O
O	O	849	857	detected	detect	B-VP	VBD	O	0	ROOT	O
O	O	858	870	gangliosides	ganglioside	B-NP	NNS	O	4	OBJ	O
O	O	871	873	in	in	B-PP	IN	O	4	VMOD	O
O	O	874	886	supernatants	supernatant	B-NP	NNS	O	6	PMOD	O
O	O	887	891	from	from	B-PP	IN	O	7	NMOD	O
O	O	892	895	RCC	RCC	B-NP	NN	B-cell_type	10	NMOD	B-cell_type
O	O	896	904	explants	explant	I-NP	NNS	I-cell_type	8	PMOD	I-cell_type
O	O	905	908	and	and	B-PP	CC	O	6	PMOD	O
O	O	909	912	not	not	I-PP	RB	O	6	PMOD	O
O	O	913	917	from	from	B-PP	IN	O	6	PMOD	O
O	O	918	926	adjacent	adjacent	B-NP	JJ	O	17	NMOD	O
O	O	927	933	normal	normal	I-NP	JJ	O	17	NMOD	O
O	O	934	940	kidney	kidney	I-NP	NN	O	17	NMOD	O
O	O	941	947	tissue	tissue	I-NP	NN	O	13	PMOD	O
O	O	947	948	.	.	O	.	O	4	P	O

O	O	949	961	Gangliosides	Ganglioside	B-NP	NNS	O	19	NMOD	O
O	O	962	970	prepared	prepare	B-VP	VBN	O	1	NMOD	O
O	O	971	975	from	from	B-PP	IN	O	2	VMOD	O
O	O	976	979	RCC	RCC	B-NP	NN	O	5	NMOD	O
O	O	980	992	supernatants	supernatant	I-NP	NNS	O	3	PMOD	O
O	O	992	993	,	,	O	,	O	19	P	O
O	O	994	996	as	as	B-CONJP	RB	O	19	NMOD	O
O	O	997	1001	well	well	I-CONJP	RB	O	7	DEP	O
O	O	1002	1004	as	as	I-CONJP	IN	O	7	DEP	O
O	O	1005	1008	the	the	B-NP	DT	O	13	NMOD	O
O	O	1009	1017	purified	purify	I-NP	VBN	O	13	NMOD	O
O	O	1018	1024	bovine	bovine	I-NP	JJ	O	13	NMOD	O
O	O	1025	1037	gangliosides	ganglioside	I-NP	NNS	O	19	NMOD	O
O	O	1038	1039	G	G	I-NP	NN	O	19	NMOD	O
O	O	1039	1040	(	(	O	(	O	17	DEP	O
O	O	1040	1042	m1	m1	B-NP	NN	O	17	DEP	O
O	O	1042	1043	)	)	O	)	O	14	NMOD	O
O	O	1044	1047	and	and	O	CC	O	19	NMOD	O
O	O	1048	1049	G	G	B-NP	NN	O	24	SUB	O
O	O	1049	1050	(	(	O	(	O	22	DEP	O
O	O	1050	1053	d1a	d1a	B-NP	NN	O	22	DEP	O
O	O	1053	1054	)	)	O	)	O	19	NMOD	O
O	O	1054	1055	,	,	O	,	O	19	P	O
O	O	1056	1066	suppressed	suppress	B-VP	VBD	O	0	ROOT	O
T10	B-Entity	1067	1075	NFkappaB	NFkappaB	B-NP	NN	B-protein	27	NMOD	B-protein
O	O	1076	1083	binding	binding	I-NP	NN	O	27	NMOD	O
O	O	1084	1092	activity	activity	I-NP	NN	O	24	OBJ	O
O	O	1093	1095	in	in	B-PP	IN	O	27	NMOD	O
O	O	1096	1097	T	T	B-NP	NN	B-cell_type	30	NMOD	B-cell_type
O	O	1098	1103	cells	cell	I-NP	NNS	I-cell_type	28	PMOD	I-cell_type
O	O	1104	1107	and	and	O	CC	O	24	VMOD	O
O	O	1108	1115	reduced	reduce	B-VP	VBN	O	24	VMOD	O
O	O	1116	1126	expression	expression	B-NP	NN	O	32	OBJ	O
O	O	1127	1129	of	of	B-PP	IN	O	33	NMOD	O
O	O	1130	1133	the	the	B-NP	DT	O	36	NMOD	O
O	O	1134	1143	cytokines	cytokine	I-NP	NNS	B-protein	43	NMOD	B-protein
T3	B-Protein	1144	1146	IL	IL	I-NP	NN	B-protein	43	NMOD	B-protein
T3	I-Protein	1146	1147	-	-	B-NP	HYPH	I-protein	37	NMOD	I-protein
T3	I-Protein	1147	1148	2	2	I-NP	CD	I-protein	38	NMOD	I-protein
O	O	1149	1152	and	and	I-NP	CC	O	43	NMOD	O
T4	B-Protein	1153	1156	IFN	IFN	I-NP	NN	B-protein	43	NMOD	B-protein
T4	I-Protein	1156	1157	-	-	I-NP	HYPH	I-protein	43	NMOD	I-protein
T4	I-Protein	1157	1162	gamma	gamma	I-NP	NN	I-protein	34	PMOD	I-protein
O	O	1162	1163	.	.	O	.	O	24	P	O

O	O	1164	1169	Taken	Take	B-VP	VBN	O	6	VMOD	O
O	O	1170	1178	together	together	B-ADVP	RB	O	1	VMOD	O
O	O	1178	1179	,	,	O	,	O	6	P	O
O	O	1180	1183	our	our	B-NP	PRP$	O	5	NMOD	O
O	O	1184	1192	findings	finding	I-NP	NNS	O	6	SUB	O
O	O	1193	1200	suggest	suggest	B-VP	VBP	O	0	ROOT	O
O	O	1201	1205	that	that	B-SBAR	IN	O	6	VMOD	O
O	O	1206	1211	tumor	tumor	B-NP	NN	O	11	NMOD	O
O	O	1211	1212	-	-	B-NP	HYPH	O	11	NMOD	O
O	O	1212	1219	derived	derive	I-NP	VBN	O	11	NMOD	O
O	O	1220	1232	gangliosides	ganglioside	I-NP	NNS	O	12	SUB	O
O	O	1233	1236	may	may	B-VP	MD	O	7	SBAR	O
O	O	1237	1242	blunt	blunt	I-VP	VB	O	12	VC	O
O	O	1243	1252	antitumor	antitumor	B-NP	JJ	O	16	NMOD	O
O	O	1253	1259	immune	immune	I-NP	JJ	O	16	NMOD	O
O	O	1260	1269	responses	response	I-NP	NNS	O	13	OBJ	O
O	O	1270	1272	in	in	B-PP	IN	O	13	VMOD	O
O	O	1273	1281	patients	patient	B-NP	NNS	O	17	PMOD	O
O	O	1282	1286	with	with	B-PP	IN	O	18	NMOD	O
O	O	1287	1291	RCCs	RCC	B-NP	NNS	O	19	PMOD	O
O	O	1291	1292	.	.	O	.	O	6	P	O
